GlaxoSmithKline Plc expects to see earnings grow again in 2016 following a reshaping of its business to focus on pharmaceuticals, vaccines and consumer healthcare and reducing its dependence on the off-patent respiratory medicine Advair. ---Subscribe to MedNous to access this article--- Company News
